AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22998014 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 293
Study 21046070 — intervention group
Group type: EXPERIMENTAL
Intervention: maintenance treatment (initial optimal therapeutic doses continued throughout the study)
Number of subjects: 404
Study 21046070 — intervention group
Group type: COMPARATOR
Intervention: dose-reduction group (initial optimal therapeutic doses continued for 4 or 26 weeks followed by a 50% dose reduction)
Number of subjects: 404
Study 19496901 — intervention group
Group type: EXPERIMENTAL
Intervention: Thienopyridine administration (500 mg ticlopidine or 300 mg clopidogrel)
Number of subjects: 1036
Study 17380456 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative intra-iliac and hepatic arterial infusion chemotherapy (group I)
Number of subjects: 84
Study 17380456 — intervention group
Group type: COMPARATOR
Intervention: Routine vein chemotherapy (group II)
Number of subjects: 84
Study 15499696 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib monotherapy (250 mg/day and 500 mg/day)
Number of subjects: 1000
Study 15499696 — intervention group
Group type: COMPARATOR
Intervention: Gefitinib
Number of subjects: 1000
Study 15499696 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib monotherapy
Number of subjects: 1000
Study 11562798 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee brace (SofTec, Bauerfeind)
Number of subjects: 46
Study 11562798 — intervention group
Group type: COMPARATOR
Intervention: Standardized physical therapy program
Number of subjects: 46
Study 9596249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 1000 mg i.v.
Number of subjects: 9
Study 9596249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide 500 mg i.v.
Number of subjects: 9
Study 7809342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group psychotherapy (CBT)
Number of subjects: 39
Study 7809342 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential group psychotherapy (ET)
Number of subjects: 39
Study 7809342 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group (WCG)
Number of subjects: 39
Study 3053888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 53
Study 3053888 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 3053888 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadolol (compliant subgroup)
Number of subjects: 53
Study 3053888 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compliant subgroup)
Number of subjects: 53
Study 31753736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended-release (MAS-ER) and topiramate
Number of subjects: 127
Study 31753736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 29668634 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 566
Study 29668634 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 566
Study 28939307 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-training FIFA 11+ exercise program
Number of subjects: 344
Study 28939307 — intervention group
Group type: COMPARATOR
Intervention: Pre FIFA 11+ program alone (Control)
Number of subjects: 344
Study 25140041 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept (ETN)
Number of subjects: 41
Study 23312079 — intervention group
Group type: EXPERIMENTAL
Intervention: HP+ (high-sensory protein)
Number of subjects: 26
Study 23312079 — intervention group
Group type: EXPERIMENTAL
Intervention: HC+ (high-sensory carbohydrate)
Number of subjects: 26
Study 23312079 — intervention group
Group type: EXPERIMENTAL
Intervention: HP2 (low-sensory protein)
Number of subjects: 26
Study 23312079 — intervention group
Group type: COMPARATOR
Intervention: LE (lower-energy drink)
Number of subjects: 26
Study 21676230 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol-rich beverage (PRB)
Number of subjects: 31
Study 18631255 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily fixed-dose combination tablet of abacavir and lamivudine (ABC/3TC FDC, Kivexa)
Number of subjects: 94
Study 18631255 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily abacavir and lamivudine (ABC and 3TC)
Number of subjects: 94
Study 17008617 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 3996
Study 17008617 — intervention group
Group type: COMPARATOR
Intervention: CABG with CPB
Number of subjects: 3996
Study 15536660 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated paste (petrolatum, 15% zinc oxide, 0.25% miconazole nitrate)
Number of subjects: 35
Study 15536660 — intervention group
Group type: COMPARATOR
Intervention: Control (non-medicated cream)
Number of subjects: 35
Study 15536660 — intervention group
Group type: EXPERIMENTAL
Intervention: Medicated paste
Number of subjects: 35
Study 10887758 — intervention group
Group type: EXPERIMENTAL
Intervention: Eating disorder diagnostic scale
Number of subjects: 367
Study 9063546 — intervention group
Group type: COMPARATOR
Intervention: IV crystalloid after no phlebotomy (control)
Number of subjects: 20
Study 9063546 — intervention group
Group type: EXPERIMENTAL
Intervention: IV crystalloid after phlebotomy
Number of subjects: 20
Study 9063546 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hoc analysis for phlebotomy group
Number of subjects: 20
Study 7677801 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive-course 5FU plus low-dose leucovorin (5FU 425 mg/m2 plus leucovorin 20 mg/m2 IV push daily for 5 days, courses repeated at 4- to 5-week intervals)
Number of subjects: 372
Study 7677801 — intervention group
Group type: COMPARATOR
Intervention: weekly 5FU plus high-dose leucovorin (5FU 600 mg/m2 IV push plus leucovorin 500 mg/m2 as a 2-hour infusion weekly for 6 weeks, courses repeated every 8 weeks)
Number of subjects: 372
Study 7677801 — intervention group
Group type: EXPERIMENTAL
Intervention: intensive-course 5FU plus low-dose leucovorin
Number of subjects: 372
Study 7677801 — intervention group
Group type: COMPARATOR
Intervention: weekly 5FU plus high-dose leucovorin
Number of subjects: 372
Study 2801549 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 1‐adrenergic blockade with optimal dose metoprolol
Number of subjects: 9
Study 2801549 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 9
Study 342620 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 CCA units of vaccine
Number of subjects: 0
Study 342620 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 CCA units of vaccine
Number of subjects: 0
Study 342620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 342620 — intervention group
Group type: EXPERIMENTAL
Intervention: Subvirion vaccines
Number of subjects: 0
Study 342620 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole‐virus vaccines
Number of subjects: 0
Study 342620 — intervention group
Group type: EXPERIMENTAL
Intervention: All vaccines
Number of subjects: 0
Study 30949708 — intervention group
Group type: EXPERIMENTAL
Intervention: Lefamulin (intravenous and oral administration)
Number of subjects: 32
Study 28333173 — intervention group
Group type: EXPERIMENTAL
Intervention: Submuscular breast augmentation
Number of subjects: 30
Study 28333173 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of total fat
Number of subjects: 522
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intake of saturated fatty acids
Number of subjects: 522
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent physical activity
Number of subjects: 522
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 522
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher waist circumference
Number of subjects: 522
Study 26812510 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight reduction prior to cognition assessment
Number of subjects: 522
Study 23823056 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disk arthroplasty with the Discover cervical disk prosthesis
Number of subjects: 32
Study 23823056 — intervention group
Group type: COMPARATOR
Intervention: ACDF with a polyetheretherketone cage and plate
Number of subjects: 32
Study 21677464 — intervention group
Group type: EXPERIMENTAL
Intervention: HAI FUDR/Dex plus IV Bev
Number of subjects: 22
Study 21677464 — intervention group
Group type: COMPARATOR
Intervention: HAI FUDR/Dex alone (no Bev)
Number of subjects: 22
Study 19537523 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine dihydrogen phosphate (1.544 mg, equivalent to 1 mg rilmenidine)
Number of subjects: 25
Study 19537523 — intervention group
Group type: COMPARATOR
Intervention: Reference product (1.544 mg rilmenidine dihydrogen phosphate)
Number of subjects: 25
Study 16403735 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g AAs/kg within the first 24 h
Number of subjects: 27
Study 16403735 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mL MEF x kg(‐1) x d(‐1) within the first 72 h
Number of subjects: 27
Study 16403735 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 27
Study 15569795 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (200 microg/kg, single dose)
Number of subjects: 31
Study 15569795 — intervention group
Group type: COMPARATOR
Intervention: Albendazole (400 mg/day for 21 days)
Number of subjects: 31
Study 11523759 — intervention group
Group type: EXPERIMENTAL
Intervention: Solitary cysticercus granuloma
Number of subjects: 0
Study 11523759 — intervention group
Group type: EXPERIMENTAL
Intervention: Management approach discussed
Number of subjects: 0
Study 8720888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010) for measuring end-tidal breath alcohol concentration (etAC)
Number of subjects: 101
Study 8720888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010) for measuring etAC
Number of subjects: 101
Study 8720888 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrochemical sensor (Alcomed 3010)
Number of subjects: 101
Study 2021717 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography plus appropriate intervention (coronary angioplasty in 169 cases, coronary grafting in 59)
Number of subjects: 800
Study 2021717 — intervention group
Group type: COMPARATOR
Intervention: Conservative care (403 patients, with 12 having angioplasty and 7 bypass grafting during initial admission)
Number of subjects: 800
Study 2021717 — intervention group
Group type: EXPERIMENTAL
Intervention: Early angiography plus appropriate intervention
Number of subjects: 800
Study 2021717 — intervention group
Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 800
Study 6800507 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient physiotherapy after medial meniscectomy
Number of subjects: 2
Study 6800507 — intervention group
Group type: COMPARATOR
Intervention: No outpatient physiotherapy after medial meniscectomy
Number of subjects: 2
Study 30278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) (≥180 s)
Number of subjects: 540
Study 30278462 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC) (≤60 s)
Number of subjects: 540
Study 30278462 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 540
Study 30278462 — intervention group
Group type: COMPARATOR
Intervention: Early cord clamping (ECC)
Number of subjects: 540
Study 28960745 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonconditional cardiac implantable electronic devices (CIEDs) during MRI scans
Number of subjects: 178
Study 25739671 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU/LV + irinotecan (experimental arm)
Number of subjects: 357
Study 25739671 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV (control arm)
Number of subjects: 357
Study 23473974 — intervention group
Group type: EXPERIMENTAL
Intervention: Empty can position
Number of subjects: 28
Study 23473974 — intervention group
Group type: EXPERIMENTAL
Intervention: Full can position
Number of subjects: 28
Study 23473974 — intervention group
Group type: COMPARATOR
Intervention: Control group (without shoulder pain)
Number of subjects: 28
Study 23473974 — intervention group
Group type: COMPARATOR
Intervention: Subacromial impingement group
Number of subjects: 28
Study 21247820 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in AS3MT
Number of subjects: 533
Study 21247820 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in DNMT genes
Number of subjects: 533
Study 21247820 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncoding AS3MT polymorphisms
Number of subjects: 533
Study 19016074 — intervention group
Group type: EXPERIMENTAL
Intervention: Baerum-model like intervention (rapid-response outreach programme) for 6 months
Number of subjects: 151
Study 19016074 — intervention group
Group type: COMPARATOR
Intervention: Control group (prospective follow-up from 2002)
Number of subjects: 151
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to beta2-glycoprotein I (abeta2GPI)
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to prothrombin (aPT)
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: IgG antibodies to annexin AV (aAnAV)
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: IgM antibodies to protein S
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: Lupus ratio of the dilute prothrombin time
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-positive patients with abeta2GPI antibodies
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-positive patients with aPT antibodies
Number of subjects: 112
Study 17440049 — intervention group
Group type: EXPERIMENTAL
Intervention: LA-positive patients with IgG abeta2GPI and aAnAV antibodies
Number of subjects: 112
Study 15345273 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine lozenges
Number of subjects: 82
Study 11224480 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO (50 IU/kg three times per week)
Number of subjects: 73
Study 11224480 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 73
Study 9521250 — intervention group
Group type: EXPERIMENTAL
Intervention: Deprenyl
Number of subjects: 36
Study 9521250 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioctic acid
Number of subjects: 36
Study 9521250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 7532060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive ablative maintenance (IM) program for 9 months
Number of subjects: 122
Study 7532060 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive, short-term consolidation (IC) using 1 cycle of intermediate-dose Ara C plus AMSA and 1 cycle of HD-AraC/AMSA
Number of subjects: 122
Study 7532060 — intervention group
Group type: COMPARATOR
Intervention: Control group (refusals) who received no further treatment after early consolidation
Number of subjects: 122
Study 2122506 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (0.1 mg.kg‐1)
Number of subjects: 12
Study 2122506 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 12
Study 342247 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (4,800 mg daily)
Number of subjects: 60
Study 342247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 342247 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 60
Study 31804729 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous cultured fibroblasts (ACFs)
Number of subjects: 21
Study 31804729 — intervention group
Group type: COMPARATOR
Intervention: Control (saline injections)
Number of subjects: 21
Study 30813256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato pomace extract (1 g)
Number of subjects: 99
Study 30813256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato pomace extract (2.5 g)
Number of subjects: 99
Study 30813256 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study 28121184 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced-exertion high-intensity interval training (REHIT) - 8 weeks, three 10-min low-intensity cycling sessions/week with two 'all-out' 10-20-s sprints
Number of subjects: 16
Study 28121184 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity walking - 8 weeks, five 30-min sessions/week at 40%-55% of heart-rate reserve
Number of subjects: 16
Study 28121184 — intervention group
Group type: COMPARATOR
Intervention: Both REHIT and moderate-intensity walking
Number of subjects: 16
Study 28121184 — intervention group
Group type: COMPARATOR
Intervention: Neither REHIT nor moderate-intensity walking
Number of subjects: 16
Study 25834670 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 226
Study 25834670 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 226
Study 25834670 — intervention group
Group type: EXPERIMENTAL
Intervention: History of stroke
Number of subjects: 226
Study 25834670 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 226
Study 23846019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 1472
Study 23846019 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/VKA
Number of subjects: 1472
Study 25214979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized lidocaine inhalation in addition to routine treatment (groups A2 and B1)
Number of subjects: 36
Study 25214979 — intervention group
Group type: COMPARATOR
Intervention: Nebulized normal saline apart from routine treatment (groups A1 and B2)
Number of subjects: 36
Study 20003208 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally- and literacy-tailored diabetes self-management intervention (Latinos en Control)
Number of subjects: 250
Study 20003208 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 250
Study 17206286 — intervention group
Group type: EXPERIMENTAL
Intervention: 8% sevoflurane
Number of subjects: 80
Study 17206286 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 80
Study 14720161 — intervention group
Group type: EXPERIMENTAL
Intervention: DC induction
Number of subjects: 37
Study 14720161 — intervention group
Group type: COMPARATOR
Intervention: T shock
Number of subjects: 37
Study 11727084 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic fundoplication (LF)
Number of subjects: 60
Study 11727084 — intervention group
Group type: COMPARATOR
Intervention: Open fundoplication (OF)
Number of subjects: 60
Study 8985267 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic rubber band ligation
Number of subjects: 47
Study 8985267 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy (ligation + sclerotherapy)
Number of subjects: 47
Study 8214740 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric warming blanket
Number of subjects: 55
Study 8214740 — intervention group
Group type: EXPERIMENTAL
Intervention: Bair Hugger
Number of subjects: 55
Study 8214740 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulated Bair Hugger
Number of subjects: 55
Study 8214740 — intervention group
Group type: COMPARATOR
Intervention: No hypothermia prevention (control group)
Number of subjects: 55
Study 2872279 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil with neuromuscular blocking agents
Number of subjects: 0
Study 2872279 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil without neuromuscular blocking agents
Number of subjects: 0
Study 31125465 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate delivery (GRIT)
Number of subjects: 741
Study 31125465 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed delivery with monitoring by conventional cardiotocography (CTG) (GRIT)
Number of subjects: 741
Study 31125465 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized CTG (cCTG) only (GRIT and TRUFFLE)
Number of subjects: 741
Study 31125465 — intervention group
Group type: EXPERIMENTAL
Intervention: cCTG and ductus venosus (DV) Doppler (TRUFFLE)
Number of subjects: 741
Study 29795315 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants with sedation-analgesia (SA)
Number of subjects: 208
Study 29795315 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants without sedation-analgesia (SA)
Number of subjects: 208
Study 29795315 — intervention group
Group type: COMPARATOR
Intervention: No exposure to SA or anticonvulsants
Number of subjects: 208
Study 29795315 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedation-analgesia (SA) alone
Number of subjects: 208
Study 27354480 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 239
Study 27354480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 24118106 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational DVD intervention for cachexia management
Number of subjects: 200
Study 22229972 — intervention group
Group type: EXPERIMENTAL
Intervention: CS-occlusion
Number of subjects: 42
Study 22229972 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study 19923089 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE combined with percutaneous lipiodol and anti-cancer agent injection into the tumor (Group B)
Number of subjects: 40
Study 19923089 — intervention group
Group type: COMPARATOR
Intervention: TACE (Group A)
Number of subjects: 40
Study 17600466 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab + chemotherapy (CEOP)
Number of subjects: 204
Study 17600466 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CEOP)
Number of subjects: 204
Study 15610371 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based elemental milk formula for 6 weeks
Number of subjects: 15
Study 15610371 — intervention group
Group type: COMPARATOR
Intervention: Pre-existing formulae (placebo) for 6 weeks
Number of subjects: 15
Study 15610371 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid-based elemental milk formula
Number of subjects: 15
Study 11429357 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hyperbaric ropivacaine (18 mg)
Number of subjects: 60
Study 11429357 — intervention group
Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine (12 mg)
Number of subjects: 60